Skip to main content

Table 3 Estimates obtained from Core Model (\(\gamma =1/7\))

From: Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2

Parameter Median (50%) Lower (2.5%) Upper (97.5%)
\(\beta\) 0.4060 0.3893 0.4425
\(e_{1A}\) 0.3851 0.3425 0.4260
\(e_{2A}\) 0.6402 0.6140 0.6647
\(e_{1P}\) 0.1954 0.1041 0.2809
\(e_{2P}\) 0.8392 0.8212 0.8559
Initial I 54.0151 48.4328 59.5435
Initial \(I_{1A}\) 14.8932 10.3012 19.8382
Initial \(I_{2A}\) 2.4775 0.9300 4.7359
Initial \(I_{1P}\) 0.7469 0.1234 2.0681
Initial \(I_{2P}\) 2.9717 1.3856 5.1267
  1. Notation is as follows \(\beta\): Transmission rate, \(e_{ij}\): Effectiveness of i doses of vaccine j against infection, Initial I: Initial number of unvaccinated infected individuals, Initial \(I_{ij}\): Initial number of infected individuals who have received i doses of vaccine j. For number of doses we have \(i\in \{1,2\}\) and for vaccines \(j\in \{A,P\}\) for Oxford-AstraZeneca and Pfizer-BioNTech respectively